The fastest way to lose control of a Latin America launch is to let the first distributor become the sanitary registration holder. The commercial conversation sounds efficient: “They already import, they already know COFEPRIS / INVIMA / ANVISA, put the certificate in their name.” Six months later the independent registration holder Latin America medical device option is gone, and every channel change becomes a regulatory project. This brief is how manufacturers avoid that lock-in — and how independent third-party titularidad keeps multi-distributor agility intact.
I am Julio Martinez-Clark, CEO of bioaccess®. We hold registrations through our own local entities for the manufacturer’s benefit. The public product card is the LATAM Launch Subscription at USD 7,500 per year per country for the first device family (published 23 August 2026). This page is strategy, not a quote. Confirm country-specific holder rules in the proposal.
1. The distributor-as-holder trap
Every major Latin American health authority ties a device registration to an in-country legal entity. That entity is the titular, detentor, representante autorizado, or registration holder. On that name sit tecnovigilancia, answers to the authority, variations, renewals, and — in several markets — importation rights. The distributor is a different job: sells, invoices, trains, services. When both jobs sit in one company, you do not have a channel partner. You have a partner who also owns the regulatory asset.
How the trap usually forms:
- Speed bias. The commercial team wants a LOI this quarter. The distributor offers to “handle registro.” Filing in their name is faster than standing up an independent holder — until you need to exit.
- Invoice confusion. Government fees and agent retainers get bundled into the distribution margin. Finance never sees a separate holder line, so nobody owns the certificate as an asset.
- Assumed portability. Teams assume “we can transfer later.” In many markets, transfer is a cesión de derechos, a new registro, or both — with months of downtime and a second full dossier.
- Single-door import. When the holder is also the exclusive importer, terminating the commercial relationship can strand inventory and freeze new shipments even if patients and hospitals still want the product.
The operating rule is simple: holder and distributor are separate roles unless you deliberately choose otherwise. Write that into the distribution LOI before anyone files. If the LOI is silent, the first filing will decide for you.
2. The cost of transferring registrations
Transfer cost is not only the government fee. It is calendar, dossier rebuild, and commercial interruption.
Mexico (COFEPRIS). The named titular on the Registro Sanitario is the sanitary face of the product. If the distributor is the name on the public Visor de Registros Sanitarios de Dispositivos Médicos, channel termination does not move the certificate. You negotiate a cesión or re-register. Either path needs a complete technical file, updated labels, and a vigilance handoff. While that runs, the outgoing holder still owns the legal duties — including tecnovigilancia under the applicable Mexican framework (including NOM-240-SSA1-2012 expectations for the titular).
Brazil (ANVISA). RDC No. 751 of 15 September 2022 names a single detentor de registro. The foreign manufacturer cannot be that detentor. Changing detentor is a regulated event, not a contract amendment. RDC 270/2019 already lets one detentor authorize several importers without re-registering the device — which is exactly why an independent Brazil Registration Holder is the correct design and a distributor-detentor is expensive to unwind.
Colombia (INVIMA). Decreto 4725 of 2005 is the sanitary-registration statute. INVIMA contemplates one titular with the ability to work through importers. Handing titularidad to the first commercializer turns every later distributor change into a regulatory file. Colombia remains a core market-access geography for bioaccess®; keep the commercial registro on an independent holder even when investigation work sits elsewhere.
Central America and single-representative markets. Panama (Ley 90 of 2017 and Decreto Ejecutivo No. 490 of 4 October 2019), El Salvador (SRS / DNM commercial track), Dominican Republic (DIGEMAPS), and similar single-authorized-representative models make holder changes especially painful: the representative is often titular and importer in one. Changing AAR frequently means registering again. Budget that as a new market entry, not a paperwork afternoon.
Hidden line items on every transfer. Certified Spanish or Portuguese retranslation if the outgoing distributor owned the glossary; new label artwork; updated importation permits; training the new vigilance contact; explaining to hospital procurement why the sanitary number’s legal face changed. Sponsors who “saved” a year-one holder fee typically spend it back in year-two exit costs — plus lost quarters of revenue.
3. Country titularidad frameworks (INVIMA, COFEPRIS, ANVISA, Central America)
Classification and holder rules diverge. Do not paste a single “Class II + local agent” row across nineteen countries.
COFEPRIS (Mexico). Reglamento de Insumos para la Salud Article 83 uses a three-class logic where duration-in-body and novelty drive Class II versus Class III. A Mexico Registration Holder that is not the exclusive distributor can name several distributors and importers on one certificate. That is the structural reason independent titularidad pays for itself in Mexico: one sanitary face, many commercial doors. Check the named titular on the public visor once the registro is vigente.
ANVISA (Brazil). Four classes under RDC 751/2022; Classes I/II often go to notificação and Classes III/IV to registro, with long statutory maximums for higher-risk files. Implantable and long-term surgically invasive devices default toward higher classes unless a specific rule says otherwise. The detentor runs the post-market system (including obligations under frameworks such as RDC 67/2009 for tecnovigilância). Independent holder plus authorized importers under RDC 270/2019 is the multi-channel design.
INVIMA (Colombia). Four classes with a IIa/IIb split under Decreto 4725 of 2005. Class I and IIa can receive registro sanitario automático; Class IIb and III take prior review on the order of roughly ninety business days. Titularidad should sit with an entity that answers to the manufacturer’s transfer doctrine — not with whichever distributor won the first tender.
Central America. Treat Panama, El Salvador, Costa Rica, Guatemala, Honduras, Nicaragua, and the Dominican Republic as a family of single-representative or tightly coupled holder–importer models, each with its own statute. The shared operating lesson: do not assume a Mexican multi-importer pattern exists. Confirm whether one authorized representative is also the only legal importer before you sign an exclusive distribution agreement that conflicts with the sanitary fact.
Argentina, Peru, Chile (for completeness). ANMAT’s authorized representative logic (Disposición 64/2025 replacing older AAR instruments), Peru’s DIGEMID droguería/titular model under Ley N° 29459 and Decreto Supremo N° 016-2011-SA (with Decreto Supremo N° 001-2024-SA supporting independent Peru Registration Holder designs), and Chile’s ISP regime all reward the same doctrine: name the holder on purpose before the channel LOI.
Ethics and trial authorization are a different desk from commercial titularidad. If you still need patients, keep the investigation file off the commercial holder track — the same separation we argue on the centralized vs decentralized ethics review brief. Mixing clocks creates rework that looks like “LATAM delay” and is actually self-inflicted file contamination.
4. Independent holder enables multi-distributor agility
Independent third-party titularidad is not a legal curiosity. It is the operating system that lets commercial strategy change without burning the sanitary asset.
What “independent” means in practice:
- The holder does not sell the device. No conflict between margin and vigilance. No incentive to slow a competitor distributor’s import authorization.
- Transfer provisions are written up front. The manufacturer can move or reclaim the registro under defined conditions without inventing a negotiation during a channel fight.
- Importer lists follow the sanitary rules of each country. Mexico, Colombia, and Brazil (under RDC 270/2019) can support multiple importers on one registration design; single-representative markets need a different commercial map. Write contracts to the sanitary fact.
- Tecnovigilancia stays continuous. Field actions, periodic reports, and authority queries do not restart every time sales leadership changes distributors.
- Translation memory stays with the manufacturer. IFU, labels, and technical-file Spanish/Portuguese should not live only on a distributor’s laptop.
Multi-distributor agility — concrete outcomes:
- Appoint a hospital-focused distributor in one region and a retail or tender-focused partner in another without splitting the registro.
- Replace an underperforming partner without a year of re-registration downtime.
- Add an importer for a new procurement channel while the same titular answers COFEPRIS, INVIMA, or ANVISA.
- Keep Global Trial Accelerators™ clinical programs and commercial launch on separate rails: investigation units use the trial importer; commercial SKUs use the holder/IOR design on the market-access hub.
bioaccess®’s published structure is that independent holder across a 19-market footprint, executed through our own local entities. As of the July 2026 market-access card: 25+ device registrations completed; 25+ active registrations held through bioaccess® entities; 15+ years on COFEPRIS, INVIMA, ANVISA, and ANMAT (self-reported). The USD 7,500/year LATAM Launch Subscription for the first device family bundles government submission fees, certified translation with manufacturer-owned translation memory, in-country titular/holder/IOR, post-approval modifications, agency liaison, and tecnovigilancia as holder. Higher-risk Mexico and Brazil SKUs and multi-country discounts are on the live card — do not invent rates here.
Site and investigator network questions for trials belong on the network page; commercial holder strategy belongs on market access. Do not hire a new local agent per capital if the plan is several certificates under one transfer doctrine.
Build the holder map before the LOI
- List every launch country and write who will be titular / detentor / AAR — manufacturer branch, independent professional holder, or distributor — on purpose.
- For each country, write who may import and whether multiple importers are legally available.
- Forbid distributor-as-holder in the LOI unless the board explicitly accepts lock-in.
- Put maintenance on a flat annual subscription so variations, renewals, and vigilance are not a new consulting event every quarter.
- Keep ethics/trial authorization off the commercial certificate path.
Learn about independent registration holding and the bioaccess® LATAM Launch Subscription at bioaccessla.com/market-access. Related: site network and centralized vs decentralized ethics review in LATAM.